chain are the CH2 and CH3 domains of an IgG antibody Fc region (**SEQ ID NO:10**);

wherein the first and the second polypeptide chains are covalently bonded to one another by a first disulfide bond and the first and third polypeptide chains are covalently bonded to one another by a second disulfide bond.

[0038a] In one aspect, there is provided a bi-specific monovalent Fc diabody, wherein said bi-specific monovalent Fc diabody is capable of specific binding to an epitope of CD32B and to an epitope of CD79b, and possesses an IgG Fc Domain, wherein said bi-specific monovalent Fc diabody comprises:

(1) a first polypeptide chain having the amino acid sequence of **SEQ ID NO:15**;

(2) a second polypeptide chain having the amino acid sequence of **SEQ ID NO:16**; and

(3) a third polypeptide chain having the amino acid sequence of **SEQ ID NO:17,** wherein amino acid residues 1-10 of said third polypeptide chain are Peptide 1 (**SEQ ID NO:1**), and amino acid residues 11-227 of said third polypeptide chain are the CH2 and CH3 domains of an IgG antibody Fc region (**SEQ ID NO:10**);

wherein said first and said second polypeptide chains are covalently bonded to one another by a first disulfide bond and said first and third polypeptide chains are covalently bonded to one another by a second disulfide bond.

[0039] In another aspect, there is provided a pharmaceutical composition comprising any of the above-described bi-specific monovalent Fc diabodies and a physiologically acceptable carrier.

[0039a] In yet another aspect, there is provided use of the above-described bi-specific monovalent Fc diabodies, or the above-described pharmaceutical composition, in the manufacture of a medicament for treating an inflammatory disease or condition.

Claim 8. A bi-specific monovalent Fc diabody, wherein said bi-specific monovalent Fc diabody is capable of specific binding to an epitope of CD32B and to an epitope of CD79b, and possesses an IgG Fc Domain, wherein said bi-specific monovalent Fc diabody comprises:

(1) a first polypeptide chain having the amino acid sequence of **SEQ ID NO:15**;

(2) a second polypeptide chain having the amino acid sequence of **SEQ ID NO:16**; and

(3) a third polypeptide chain having the amino acid sequence of **SEQ ID NO:17,** wherein amino acid residues 1-10 of said third polypeptide chain are Peptide 1 (**SEQ ID NO:1**), and amino acid residues 11-227 of said third polypeptide chain are the CH2 and CH3 domains of an IgG antibody Fc region (**SEQ ID NO:10**);

wherein said first and said second polypeptide chains are covalently bonded to one another by a first disulfide bond and said first and third polypeptide chains are covalently bonded to one another by a second disulfide bond.

Claim 9. A pharmaceutical composition comprising the bi-specific monovalent Fc diabody of any of claims 1-8 and a physiologically acceptable carrier.

Claim 10. Use of the bi-specific monovalent Fc diabody of any one of claims 1-8, or the pharmaceutical composition of claim 9, in the manufacture of a medicament for treating an inflammatory disease or condition.

Claim 11. The use of claim 10, wherein said inflammatory disease or condition is an autoimmune disease.

Claim 12. The use of claim 11, wherein said autoimmune disease is systemic lupus erythematosus (SLE).

Claim 13. The use of claim 10, wherein said inflammatory disease or condition is graft vs. host disease (GvHD).